Carelane

Carelane is a German health-tech company, founded in Bremen in 2023 by Gustav Vella and Yannick Boerner, aiming to enhance the efficiency of clinical trials. The founders, both with extensive backgrounds in health technology through work with government bodies, private companies, and research hospitals in Germany, serve as CEO (Vella) and CTO (Boerner). Their collective experience motivated them to create a solution that empowers researchers by saving time and resources.

The company operates in the clinical research software market, providing a unified, end-to-end platform for organizations conducting clinical trials. Its client base includes pharmaceutical companies, contract research organizations (CROs), academic researchers, and health systems. Carelane targets a range of clients, from small biotechs to large research institutions, with a model that scales to the user's needs. The business model is centered on its software platform, which streamlines the entire clinical trial lifecycle—from protocol design and study setup to data management and analysis.

Carelane’s core product is an AI-native clinical research hub that consolidates numerous functions into a single system. This integrated platform is designed to eliminate the data and personnel silos often created by using multiple, disconnected software solutions. Key features include tools for protocol authoring, Electronic Data Capture (EDC), eConsent, patient management, data analysis, and document management. A significant differentiator is its use of AI to automate manual tasks, assist in planning, and monitor data in real-time. The platform digitizes study protocols into structured documents based on FHIR standards, which helps reduce costly amendments and ensures data is synchronized across systems. This approach claims to reduce trial management burdens by up to 80%. The platform also offers features for managing trial processes like sample shipments and site onboarding, all while maintaining a unified audit trail for regulatory compliance.

The company has achieved notable financial milestones, securing €800,000 in a pre-seed funding round in June 2024, led by High-Tech Gründerfonds (HTGF). This was followed by a larger seed funding round of €2.6 million in April 2025, led by Vorwerk Ventures with continued participation from HTGF and private investors. This capital is being used to expand sales, enhance the technological infrastructure, and further develop its AI capabilities.

Keywords: clinical trial management, health-tech, clinical research software, AI in clinical trials, protocol design, electronic data capture (EDC), eConsent, patient-reported outcomes (ePRO), contract research organizations (CRO), pharmaceutical research, study protocol digitization, site management, real-world evidence, clinical data management, trial automation, regulatory compliance software, FHIR standards, life sciences technology, study startup, data validation, research collaboration platform